Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,otherCurrentLiab,otherLiab,otherCurrentAssets,deferredLongTermAssetCharges,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,EPZM,-13424000.0,101976000,,,-64363000,,-64363000,33891000,-24340000,-58231000,-58231000,,-6078000,,,,0,13010000,71241000,37350000,-6132000,,-64363000,-64363000,44926000.0,1154844000.0,284920000.0,31502000.0,352549000.0,10000.0,-1123350000.0,-2000.0,18050000.0,80164000.0,40893000.0,-2000.0,17085000.0,272488000.0,163842000.0,7119000.0,231195000.0,1074000.0,7295000.0,,,,,61080000.0,-3070000.0,60978000.0,2146000.0,1366000.0,2251000.0,6453000.0,-56671000.0,1313000.0,-2273000.0,2645000.0,-105000.0,7517000.0,-102000.0,,231595000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,5.295,1630509722,0.13500023,5.15,5.325,5.15,920425,-2.440092,0.852,6.17,-0.875,-0.14181523,8.026522,-2.7315216,-0.340312,539962944,-2.6742425,6.214789,15,America/New_York,EDT,False,False,USD,-2.17,us_market,"Epizyme, Inc.",NMS,REGULAR,2,2.6162837,5.15 - 5.325,5.16,5.29,5.3,8,8,finmb_54339075,NasdaqGS,"Epizyme, Inc.",USD,1107479,853983,0.5750003,0.1218221,4.72 - 14.3,-9.005,-0.6297203,4.72,14.3,1620304200,1636029000,0,1636374600,-2.473,-1.98,-14400000,1.2,,,14.3,4.72,6.17,8.03,1.11M,853.98k,101.98M,,73.04M,4.14%,97.76%,12.34M,12.34,19.02%,12.07%,11.89M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,-733.77%,-38.32%,-142.35%,32.58M,0.32,427.40%,-100.24M,-230.86M,-256.94M,-2.47,,244.01M,2.39,248.96M,368.12,6.66,0.85,-227.89M,-114.27M,Value,02139,Healthcare,304,9,2,"Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; and HUTCHMED (China) Limited. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 229 5872,MA,7,1609372800,1625097600,7,United States,http://www.epizyme.com,86400,8,400 Technology Square,617 349 0707,Biotechnology,4th Floor
t-1,EPZM,40940000.0,101976000,,,-70274000,,-70274000,36411000,-27926000,-64337000,-64337000,,-6046000,,,,0,7631000,71968000,35557000,-5937000,,-70274000,-70274000,45964000.0,1145875000.0,283680000.0,86904000.0,406711000.0,10000.0,-1058987000.0,6000.0,2023000.0,73711000.0,39006000.0,6000.0,18307000.0,340417000.0,225232000.0,9764000.0,230504000.0,14817000.0,5357000.0,5000000.0,20000.0,,,-20200000.0,184000.0,-20319000.0,1390000.0,-3788000.0,1390000.0,-94504000.0,-75575000.0,1282000.0,-4356000.0,-6659000.0,-105000.0,7848000.0,-119000.0,,301411000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,5.295,1630509722,0.13500023,5.15,5.325,5.15,920425,-2.440092,0.852,6.17,-0.875,-0.14181523,8.026522,-2.7315216,-0.340312,539962944,-2.6742425,6.214789,15,America/New_York,EDT,False,False,USD,-2.17,us_market,"Epizyme, Inc.",NMS,REGULAR,2,2.6162837,5.15 - 5.325,5.16,5.29,5.3,8,8,finmb_54339075,NasdaqGS,"Epizyme, Inc.",USD,1107479,853983,0.5750003,0.1218221,4.72 - 14.3,-9.005,-0.6297203,4.72,14.3,1620304200,1636029000,0,1636374600,-2.473,-1.98,-14400000,1.2,,,14.3,4.72,6.17,8.03,1.11M,853.98k,101.98M,,73.04M,4.14%,97.76%,12.34M,12.34,19.02%,12.07%,11.89M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,-733.77%,-38.32%,-142.35%,32.58M,0.32,427.40%,-100.24M,-230.86M,-256.94M,-2.47,,244.01M,2.39,248.96M,368.12,6.66,0.85,-227.89M,-114.27M,Value,02139,Healthcare,304,9,2,"Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; and HUTCHMED (China) Limited. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 229 5872,MA,7,1609372800,1625097600,7,United States,http://www.epizyme.com,86400,8,400 Technology Square,617 349 0707,Biotechnology,4th Floor
t-2,EPZM,101768000.0,101976000,,,-66119000,,-66233000,35017000,-27128000,-62145000,-62145000,,-4178000,,,,114000,8375000,70520000,35503000,-3974000,,-66233000,-66233000,47002000.0,1137470000.0,288676000.0,148770000.0,473573000.0,10000.0,-988713000.0,3000.0,2021000.0,168215000.0,43400000.0,3000.0,19457000.0,405093000.0,205391000.0,3474000.0,229846000.0,10461000.0,10163000.0,,21000.0,12646000.0,114000.0,-19193000.0,-1037000.0,-19479000.0,147387000.0,6340000.0,417000.0,74793000.0,-53115000.0,4308000.0,-2304000.0,1506000.0,-3030000.0,4159000.0,-286000.0,150000000.0,361693000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,5.295,1630509722,0.13500023,5.15,5.325,5.15,920425,-2.440092,0.852,6.17,-0.875,-0.14181523,8.026522,-2.7315216,-0.340312,539962944,-2.6742425,6.214789,15,America/New_York,EDT,False,False,USD,-2.17,us_market,"Epizyme, Inc.",NMS,REGULAR,2,2.6162837,5.15 - 5.325,5.16,5.29,5.3,8,8,finmb_54339075,NasdaqGS,"Epizyme, Inc.",USD,1107479,853983,0.5750003,0.1218221,4.72 - 14.3,-9.005,-0.6297203,4.72,14.3,1620304200,1636029000,0,1636374600,-2.473,-1.98,-14400000,1.2,,,14.3,4.72,6.17,8.03,1.11M,853.98k,101.98M,,73.04M,4.14%,97.76%,12.34M,12.34,19.02%,12.07%,11.89M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,-733.77%,-38.32%,-142.35%,32.58M,0.32,427.40%,-100.24M,-230.86M,-256.94M,-2.47,,244.01M,2.39,248.96M,368.12,6.66,0.85,-227.89M,-114.27M,Value,02139,Healthcare,304,9,2,"Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; and HUTCHMED (China) Limited. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 229 5872,MA,7,1609372800,1625097600,7,United States,http://www.epizyme.com,86400,8,400 Technology Square,617 349 0707,Biotechnology,4th Floor
t-3,EPZM,160241000.0,101976000,,,-56073000,,-56073000,30575000,-23780000,-54355000,-54355000,,-2149000,,,,0,3566000,57921000,27346000,-1718000,,-56073000,-56073000,48041000.0,1130632000.0,137347000.0,208282000.0,381756000.0,10000.0,-922480000.0,120000.0,1995000.0,93422000.0,34780000.0,120000.0,20535000.0,311185000.0,186485000.0,4611000.0,82255000.0,8157000.0,7370000.0,23000.0,3827000.0,,,17987000.0,2804000.0,17722000.0,1073000.0,3700000.0,1073000.0,-23730000.0,-42525000.0,1312000.0,1707000.0,-2864000.0,-3030000.0,6798000.0,-265000.0,150000000.0,276405000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,5.295,1630509722,0.13500023,5.15,5.325,5.15,920425,-2.440092,0.852,6.17,-0.875,-0.14181523,8.026522,-2.7315216,-0.340312,539962944,-2.6742425,6.214789,15,America/New_York,EDT,False,False,USD,-2.17,us_market,"Epizyme, Inc.",NMS,REGULAR,2,2.6162837,5.15 - 5.325,5.16,5.29,5.3,8,8,finmb_54339075,NasdaqGS,"Epizyme, Inc.",USD,1107479,853983,0.5750003,0.1218221,4.72 - 14.3,-9.005,-0.6297203,4.72,14.3,1620304200,1636029000,0,1636374600,-2.473,-1.98,-14400000,1.2,,,14.3,4.72,6.17,8.03,1.11M,853.98k,101.98M,,73.04M,4.14%,97.76%,12.34M,12.34,19.02%,12.07%,11.89M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,-733.77%,-38.32%,-142.35%,32.58M,0.32,427.40%,-100.24M,-230.86M,-256.94M,-2.47,,244.01M,2.39,248.96M,368.12,6.66,0.85,-227.89M,-114.27M,Value,02139,Healthcare,304,9,2,"Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; and HUTCHMED (China) Limited. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 229 5872,MA,7,1609372800,1625097600,7,United States,http://www.epizyme.com,86400,8,400 Technology Square,617 349 0707,Biotechnology,4th Floor
